Akt-dependent and -independent mechanisms of mTOR regulation in cancer.

[1]  B. Viollet,et al.  Beyond AICA riboside: In search of new specific AMP‐activated protein kinase activators , 2009, IUBMB life.

[2]  Weiqin Jiang,et al.  Modulation of the activities of AMP‐activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2‐deoxyglucose , 2008, Molecular carcinogenesis.

[3]  H. A. Brown,et al.  Phospholipase D1 is an effector of Rheb in the mTOR pathway , 2008, Proceedings of the National Academy of Sciences.

[4]  David M. Sabatini,et al.  The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1 , 2008, Science.

[5]  Xu Huang,et al.  Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. , 2008, The Biochemical journal.

[6]  M. Wangpaichitr,et al.  Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-d-glucose under hypoxia in lung cancer cell lines , 2008, Molecular Cancer Therapeutics.

[7]  H. Lane,et al.  Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function , 2008, The Journal of Neuroscience.

[8]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[9]  M. Zou,et al.  Phosphorylation of LKB1 at Serine 428 by Protein Kinase C-&zgr; Is Required for Metformin-Enhanced Activation of the AMP-Activated Protein Kinase in Endothelial Cells , 2008, Circulation.

[10]  C. Amos,et al.  Suppression of Peutz-Jeghers Polyposis by Targeting Mammalian Target of Rapamycin Signaling , 2008, Clinical Cancer Research.

[11]  Nancy Lee,et al.  Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model , 2008, BMC dermatology.

[12]  B. Kemp,et al.  Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. , 2008, Cancer research.

[13]  D. Sgroi,et al.  Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. , 2008, Genes & development.

[14]  V. Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[15]  M. Shi,et al.  Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. , 2007, Cancer letters.

[16]  N. Sonenberg,et al.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. , 2007, Cancer research.

[17]  B. Viollet,et al.  Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase* , 2007, Journal of Biological Chemistry.

[18]  Shari Bolen,et al.  Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus , 2007, Annals of Internal Medicine.

[19]  D. Neil Hayes,et al.  LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.

[20]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[21]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[22]  V. Mieulet,et al.  A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. , 2007, The Biochemical journal.

[23]  D. Carling,et al.  Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. , 2007, The Biochemical journal.

[24]  S. Carr,et al.  PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. , 2007, Molecular cell.

[25]  H. Clevers,et al.  Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer , 2007, Oncogene.

[26]  Timothy J. Griffin,et al.  Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 , 2007, Nature Cell Biology.

[27]  B. Viollet,et al.  A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. , 2007, American journal of physiology. Renal physiology.

[28]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[29]  Ming You,et al.  TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth , 2006, Cell.

[30]  M. Konopleva,et al.  Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.

[31]  Shi-Yong Sun,et al.  LKB1 mutation in large cell carcinoma of the lung. , 2006, Lung cancer.

[32]  D. Carling,et al.  Thrombin Activates AMP-Activated Protein Kinase in Endothelial Cells via a Pathway Involving Ca2+/Calmodulin-Dependent Protein Kinase Kinase β , 2006, Molecular and Cellular Biology.

[33]  Kevin M. Ryan,et al.  DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis , 2006, Cell.

[34]  S. Berberich,et al.  Altered gene expression induced by ionizing radiation and glycolytic inhibitor 2-deoxy-glucose in a human glioma cell line: Implications for radio sensitization , 2006, Cancer biology & therapy.

[35]  L. Kifle,et al.  Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. , 2006, Cell metabolism.

[36]  C. Walker,et al.  Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning , 2006, The Journal of cell biology.

[37]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[38]  S. Chien,et al.  The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Miao Zhang,et al.  Activation of Protein Kinase Cζ by Peroxynitrite Regulates LKB1-dependent AMP-activated Protein Kinase in Cultured Endothelial Cells* , 2006, Journal of Biological Chemistry.

[40]  M. Sajan,et al.  Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects , 2006, Diabetologia.

[41]  Shailendra Giri,et al.  5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside Inhibits Cancer Cell Proliferation in Vitro and in Vivo via AMP-activated Protein Kinase* , 2005, Journal of Biological Chemistry.

[42]  F. Natt,et al.  Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  James T. Murray,et al.  hVps34 Is a Nutrient-regulated Lipid Kinase Required for Activation of p70 S6 Kinase* , 2005, Journal of Biological Chemistry.

[44]  A. Means,et al.  The Ca2+/Calmodulin-dependent Protein Kinase Kinases Are AMP-activated Protein Kinase Kinases* , 2005, Journal of Biological Chemistry.

[45]  Wolfgang Eiermann,et al.  Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Weiqin Jiang,et al.  2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. , 2005, Cancer research.

[48]  R. Heath,et al.  Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. , 2005, Cell metabolism.

[49]  A. Edelman,et al.  Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. , 2005, Cell metabolism.

[50]  C. Johannessen,et al.  Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1 , 2005, Molecular and Cellular Biology.

[51]  R. Deberardinis,et al.  The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.

[52]  C. Proud,et al.  The Tuberous Sclerosis Protein TSC2 Is Not Required for the Regulation of the Mammalian Target of Rapamycin by Amino Acids and Certain Cellular Stresses* , 2005, Journal of Biological Chemistry.

[53]  B. Dwarakanath,et al.  Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells , 2005, International journal of radiation biology.

[54]  Russell G. Jones,et al.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. , 2005, Molecular cell.

[55]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[56]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[57]  K. Inoki,et al.  The Stress-inducted Proteins RTP801 and RTP801L Are Negative Regulators of the Mammalian Target of Rapamycin Pathway* , 2005, Journal of Biological Chemistry.

[58]  Hongbing Zhang,et al.  Pathogenesis of Tuberous Sclerosis Subependymal Giant Cell Astrocytomas: Biallelic Inactivation of TSC1 or TSC2 Leads to mTOR Activation , 2004, Journal of neuropathology and experimental neurology.

[59]  E. Hafen,et al.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. , 2004, Genes & development.

[60]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[61]  B. Hemmings,et al.  Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase*♦ , 2004, Journal of Biological Chemistry.

[62]  Takehiko Sasaki,et al.  Essential Role for Phospholipase D2 Activation Downstream of ERK MAP Kinase in Nerve Growth Factor-stimulated Neurite Outgrowth from PC12 Cells* , 2004, Journal of Biological Chemistry.

[63]  D. A. Foster.  Targeting mTOR-mediated survival signals in anticancer therapeutic strategies , 2004, Expert review of anticancer therapy.

[64]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[65]  R. DePinho,et al.  Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. , 2004, Genes & development.

[66]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[67]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[68]  P. Dennis,et al.  Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. , 2004, Cancer research.

[69]  Túlio Marcos Santos,et al.  Phosphorylation of Tuberin as a Novel Mechanism for Somatic Inactivation of the Tuberous Sclerosis Complex Proteins in Brain Lesions , 2004, Cancer Research.

[70]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  N. Savaraj,et al.  2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.

[72]  In-Hyun Park,et al.  PLD1 Regulates mTOR Signaling and Mediates Cdc42 Activation of S6K1 , 2003, Current Biology.

[73]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[74]  Hongbing Zhang,et al.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. , 2003, The Journal of clinical investigation.

[75]  Jérôme Boudeau,et al.  Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade , 2003, Journal of biology.

[76]  D. Brat,et al.  Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  J. Howell,et al.  A Novel Hypoxia-inducible Factor-independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its Targets* , 2003, Journal of Biological Chemistry.

[78]  D. Sidransky,et al.  LKB1 protein expression in the evolution of glandular neoplasia of the lung. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  D. Hardie,et al.  Management of cellular energy by the AMP‐activated protein kinase system , 2003, FEBS letters.

[80]  D. A. Foster,et al.  Phospholipase D confers rapamycin resistance in human breast cancer cells , 2003, Oncogene.

[81]  R. Aft,et al.  2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. , 2003, Cancer research.

[82]  E. Hafen,et al.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. , 2003, Molecular cell.

[83]  Hongbing Zhang,et al.  Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma , 2003, The Lancet.

[84]  K. Inoki,et al.  The p38 and MK2 Kinase Cascade Phosphorylates Tuberin, the Tuberous Sclerosis 2 Gene Product, and Enhances Its Interaction with 14-3-3* , 2003, The Journal of Biological Chemistry.

[85]  J. Testa,et al.  Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. , 2003, American journal of respiratory and critical care medicine.

[86]  M. Birnbaum,et al.  Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner* , 2003, The Journal of Biological Chemistry.

[87]  N. Kimura,et al.  A possible linkage between AMP‐activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway , 2003, Genes to cells : devoted to molecular & cellular mechanisms.

[88]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[89]  B. Hemmings,et al.  Identification of a Plasma Membrane Raft-Associated PKB Ser473 Kinase Activity that Is Distinct from ILK and PDK1 , 2002, Current Biology.

[90]  J. Blenis,et al.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.

[91]  Olle Ljunqvist,et al.  Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. , 2002, Diabetes.

[92]  David Sidransky,et al.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.

[93]  Young-Bum Kim,et al.  Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature.

[94]  Jie Chen,et al.  Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling , 2001, Science.

[95]  T. Nishimoto,et al.  Novel G Proteins, Rag C and Rag D, Interact with GTP-binding Proteins, Rag A and Rag B* , 2001, The Journal of Biological Chemistry.

[96]  B. Kemp,et al.  AMP-Activated Protein Kinase Is Activated by the Stimulations of Gq-Coupled Receptors , 2000 .

[97]  Christine C. Hudson,et al.  A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. , 2000, Cancer research.

[98]  A. Newton,et al.  Akt/Protein Kinase B Is Regulated by Autophosphorylation at the Hypothetical PDK-2 Site* , 2000, The Journal of Biological Chemistry.

[99]  P. Edwards,et al.  Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism , 1999, Oncogene.

[100]  K. Jakobs,et al.  Phospholipase D Stimulation by Receptor Tyrosine Kinases Mediated by Protein Kinase C and a Ras/Ral Signaling Cascade* , 1999, The Journal of Biological Chemistry.

[101]  D. Alessi,et al.  Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. , 1999, The Biochemical journal.

[102]  W. Winder,et al.  Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. , 1999, Journal of applied physiology.

[103]  J. Exton.  Regulation of phospholipase D. , 1999, FEBS letters.

[104]  A. Casamayor,et al.  PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2 , 1999, Current Biology.

[105]  A. Edelman,et al.  Components of a Calmodulin-dependent Protein Kinase Cascade , 1998, The Journal of Biological Chemistry.

[106]  J. Woodgett,et al.  Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[107]  P. Cohen,et al.  Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha. , 1998, The Biochemical journal.

[108]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[109]  P. Cohen,et al.  Role of Translocation in the Activation and Function of Protein Kinase B* , 1997, The Journal of Biological Chemistry.

[110]  M. Andjelkovic,et al.  High Affinity Binding of Inositol Phosphates and Phosphoinositides to the Pleckstrin Homology Domain of RAC/Protein Kinase B and Their Influence on Kinase Activity* , 1997, The Journal of Biological Chemistry.

[111]  B. Dwarakanath,et al.  Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. , 1996, International journal of radiation oncology, biology, physics.

[112]  D. Hardie,et al.  5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.

[113]  J. Reves,et al.  An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group. , 1994, Anesthesia and analgesia.

[114]  H. Gruber,et al.  AICA‐Riboside: Safety, Tolerance, and Pharmacokinetics of a Novel Adenosine‐Regulating Agent , 1991, Journal of clinical pharmacology.

[115]  Richard J. Shaw.  Inaugural Article: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress , 2004 .

[116]  M. Carlson,et al.  Supplemental Data LKB 1 Is the Upstream Kinase in the AMP-Activated Protein Kinase Cascade , 2003 .